BRIEF published on 07/07/2025 at 15:05, 6 months 29 days ago Applied DNA Sciences se conforme aux normes de cotation du Nasdaq Biotechnologie Sciences Appliquées De L'ADN Conformité Au Nasdaq Technologies De L'ADN LineaRx
BRIEF published on 07/07/2025 at 15:05, 6 months 29 days ago Applied DNA Sciences Complies with Nasdaq Listing Standards Biotechnology Nasdaq Compliance Applied DNA Sciences DNA Technologies LineaRx
PRESS RELEASE published on 07/07/2025 at 15:00, 6 months 29 days ago Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements Applied DNA Sciences regains compliance with Nasdaq listing rule requiring minimum bid price of $1.00 per share. Company's securities to remain listed on Nasdaq Capital Market Nasdaq Compliance Applied DNA Sciences Nasdaq Capital Market Minimum Bid Price PCR-based DNA Technologies
BRIEF published on 06/17/2025 at 22:15, 7 months 18 days ago Transition de direction chez Applied DNA : le Dr Hayward, PDG, prend sa retraite Biotechnologie Changement De Direction Valeur Actionnariale ADN Appliqué Judy Murrah
BRIEF published on 06/17/2025 at 22:15, 7 months 18 days ago Leadership Transition at Applied DNA as CEO Dr. Hayward Retires Biotechnology Shareholder Value Leadership Change Applied DNA Judy Murrah
PRESS RELEASE published on 06/17/2025 at 22:10, 7 months 18 days ago Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward Judy Murrah appointed Chairperson and CEO of Applied DNA Sciences, succeeding Dr. James A. Hayward. Experienced executive aims to lead company's innovative DNA technologies CEO Appointment Applied DNA Sciences DNA Technologies Judy Murrah Dr. James A. Hayward
BRIEF published on 05/15/2025 at 22:10, 8 months 21 days ago Applied DNA Sciences enregistre une croissance modeste de ses revenus au deuxième trimestre 2025 Croissance Des Revenus Restructuration Stratégique Résultats Financiers Du Deuxième Trimestre Tendances Biopharmaceutiques Technologie De L'ADN
BRIEF published on 05/15/2025 at 22:10, 8 months 21 days ago Applied DNA Sciences Sees Modest Revenue Growth in Q2 2025 Revenue Growth Strategic Restructuring Q2 Financial Results DNA Technology Biopharma Trends
PRESS RELEASE published on 05/15/2025 at 22:05, 8 months 21 days ago Applied DNA Reports Second Quarter Fiscal 2025 Financial Results Applied DNA Sciences, Inc. (NASDAQ:APDN) reports a 44% Y/Y increase in LineaRx segment revenues contributing to a 6% total revenue growth. Strategic priorities and financial highlights for Q2 2025 disclosed Financial Results Strategic Priorities Applied DNA Sciences LineaRx Segment Therapeutic DNA Production
BRIEF published on 05/14/2025 at 17:35, 8 months 22 days ago Applied DNA Sciences publiera ses résultats financiers du deuxième trimestre et organisera une mise à jour pour les investisseurs Sciences Appliquées De L'ADN Conférence Téléphonique Pour Les Investisseurs Priorités Stratégiques Rediffusion Du Webcast Résultats Financiers Du Deuxième Trimestre 2025
Published on 02/05/2026 at 23:00, 26 minutes ago Grounded People Announces Non-Brokered Private Placement and Strategic Review
Published on 02/05/2026 at 21:00, 2 hours 26 minutes ago Kidoz Welcomes CloudX Innovation Driving Fairer Mobile Advertising Auctions
Published on 02/05/2026 at 18:50, 4 hours 36 minutes ago Athena Gold Provides Exploration Update From Nevada and Ontario
Published on 02/05/2026 at 17:35, 5 hours 51 minutes ago Pentagon I Capital Corp. Enters into Letter Agreement to Complete Qualifying Transaction with Prospectiva Resources Ltd.
Published on 02/05/2026 at 19:27, 3 hours 58 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 4 hours 39 minutes ago EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 5 hours 16 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 5 hours 30 minutes ago Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 5 hours 46 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.
Published on 02/05/2026 at 19:15, 4 hours 11 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 4 hours 11 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 4 hours 11 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
